Filing Flows › Comparisons › IMA vs ATRA
ImageneBio vs Atara Biotherapeutics: IMA and ATRA compared
ImageneBio is the larger company: $800K of revenue in its latest quarter (Q1 2025) against $630K for Atara Biotherapeutics (Q2 2026).
Where the money goes: IMA and ATRA
ImageneBio (IMA) · Q1 2025
ImageneBio, Q1 2025: revenue $800K, net loss $8.6M, operating cash flow −$10.6M. The chart follows the revenue to costs, profit and cash.
Atara Biotherapeutics (ATRA) · Q2 2026
Atara Biotherapeutics, Q2 2026: revenue $630K (-96% year over year), operating margin -749.2%, net loss $4.8M, operating cash flow −$3.3M. The chart follows the revenue to costs, profit and cash.
| ImageneBio (IMA) | Atara Biotherapeutics (ATRA) | |
|---|---|---|
| Latest quarter | Q1 2025 | Q2 2026 |
| Revenue | $800K | $630K |
| Revenue growth, Y/Y | — | -96% |
| Operating margin | n/m | -749.2% |
| Net earnings | −$8.6M | −$4.8M |
| Net margin | — | -767.3% |
| Operating cash flow | −$10.6M | −$3.3M |
Questions
Which is bigger, ImageneBio or Atara Biotherapeutics?
ImageneBio is the larger company: $800K of revenue in its latest quarter (Q1 2025) against $630K for Atara Biotherapeutics (Q2 2026).
More: ImageneBio earnings · how ImageneBio makes money · Atara Biotherapeutics earnings · how Atara Biotherapeutics makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed May 8, 2025; 10-Q filed Aug 12, 2026). Fiscal quarters can end on different dates. Not investment advice.